Biotechnology Commitment by Pharma Industry and its evolution vs Biotech Companies in Healthcare, Drug Development, and Business, Past & Present [2001-2022]

Abstract

What is the commitment of the pharma industry to biotechnology in its research, products, and business practices? Five issues demonstrate the pharma companies’ extensive engagement with and embrace of biotechnology as a primary focus in their business practices (marketing, sales, acquisitions) and research over the timeframe of 2000 through 2022. Overall trends for biotechnology [1980 to 2000 to 2022] are explored for context and display the overall extent of biotech impact on products approved (number and types), their breadth of indications, and extent of utilization/sales. Discovery of biotech molecules addresses pharma versus biotech companies’ results, significantly favoring biotech companies. The top 100 biotech products and drugs are discussed for 2001 versus 2011 versus 2021, especially changes over time, with pharma growth exceeding biotech companies. The top pharma & biotech companies are examined for marketing of biotech products, again showing dramatic expansion of pharma engagement. Mergers and acquisitions of biotech companies by pharma companies is presented, especially the extensive investments and breadth and depth of pharma companies engaged. All these parameters (products, companies, research, sales, company acquisitions) well documents the movement of pharma companies collectively to substantially incorporate biotech products into their research pipelines and product portfolios.